Loading
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Previous close
$0.4053
−$0.0418 · -9.35%
After-hours
$0.415
+$0.0097 · +2.39%
Oct 9, 7:46 PM ET
Regular session · ET · Market data may be delayed.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Day range
Current $0.4053
52-week range
Current $0.4053
Regular session · ET · Market data may be delayed.
GoAI Score
Strong sell
Valuation
11
Overpriced
Sentiment
44
Mixed
Risk
82
Extreme Risk
Momentum
23
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Day range
Current $0.4053
52-week range
Current $0.4053
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.04M USD | — | — | 1.57M USD | 1.26M USD |
| Cost of goods sold | 17.05M USD | 7.19M USD | 76.55M USD | 8.26M USD | 61.34M USD |
| Gross profit | −15.01M USD | −7.19M USD | −76.55M USD | −6.69M USD | −60.08M USD |
| Research and development | 69.3M USD | 88.6M USD | 76.55M USD | 63.26M USD | 61.34M USD |
| Selling, general, and administrative | 31.17M USD | 25.8M USD | 20.39M USD | 22.88M USD | 21.13M USD |
| Operating expenses | 92.43M USD | 107.21M USD | 23.5M USD | 77.89M USD | 21.13M USD |
| Interest income | 2.59M USD | 4.1M USD | 5.47M USD | 2.63M USD | 16K USD |
| Interest expense | 11.25M USD | 9.28M USD | 6.6M USD | 6.2M USD | 4.35M USD |
| Depreciation and amortization | 7.35M USD | 7.19M USD | 7.72M USD | 8.21M USD | 8.24M USD |
| Operating income | −107.44M USD | −114.4M USD | −100.05M USD | −84.58M USD | −81.21M USD |
| Net income | −40.83M USD | −148.7M USD | −110.78M USD | −11.97M USD | −26.48M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$2.00
393.46% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.64M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF1.28M0.00%95.4B USD0.05%$235+0.80%
iShares Biotechnology ETFIBB851.82K0.01%10.28B USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA604.39K0.00%21.73B USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT461.12K0.00%22B USD0.09%$319.01+1.64%
Invesco RAFI US 1500 Small-Mid ETFPRFZ190.85K0.01%2.65B USD0.36%$53.16+0.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM70K0.06%116.88M USD0.73%$15.9402+0.25%
Invesco Nasdaq Biotechnology ETFIBBQ9.21K0.01%108.26M USD0.19%$34.62+2.96%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco Nasdaq Biotechnology ETFIBBQAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
